Clinical Trials

Inclusion Criteria:

• ≥ 40 years of age.
• Diagnosed with IPF according to 2018 ATS/ERS/JRS/ALAT, confirmed by enrolling investigator.
• Signed informed consent.
• If taking pirfenidone or nintedanib, must be on stable dose for at least 6 weeks prior to enrollment visit.
• Confirmed rs3570920 TT TOLLIP genotype.

Exclusion Criteria:

• Pregnancy or planning to become pregnant -Women of childbearing potential not willing to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year during study participation.
• Significant medical, surgical or psychiatric illness that in the opinion of the investigator would affect subject safety, including liver and renal failure.
• Receipt of an investigational drug or biological agent within the previous 4 weeks of the screening visit or 5 times the half-life, if longer.
• Supplemental or prescribed NAC therapy within 60 days of enrollment.
• Listed for lung transplantation at the time of screening.
• History of lung cancer.
• Inability to perform spirometry.
• Forced vital capacity (FVC) less than 45% predicted, using the global lung function index (GLI) equation at Visit 1.
• Active respiratory infection requiring treatment with antibiotics within 4 weeks of Visit 1.